| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0009609> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0010661> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0033607> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0038477> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0069065> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0148447> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0162743> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C0206750> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C3489666> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C3694279> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C5392141> <https://research.tib.eu/covid-19/entity/32490889_HAS_TOPIC_C5392150>
?:authorAffiliation	[\'Laboratório de Proteômica Estrutural e Computacional, Instituto Carlos Chagas, Fundação Oswaldo Cruz-Fiocruz, Curitiba, PR, Brazil.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Biembengut_%C3%8Dsis_Venturi> <https://research.tib.eu/covid-19/entity/de_Souza_Tatiana_de_Arruda_Campos_Brasil>
?:doi	<https://research.tib.eu/covid-19/entity/S0074-0276202000010040710.1590/0074-02760200179>
?:doi	S0074-0276202000010040710.1590/0074-02760200179
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article>
?:journal	Memorias do Instituto Oswaldo Cruz
is ?:pmid of	<https://research.tib.eu/covid-19/entity/32490889>
?:pmid	<https://research.tib.eu/covid-19/entity/32490889>
?:pmid	32490889
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.172
?:rankingScore_hIndex	76
?:title	Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2020

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/32490889>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/32490889>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all